EZH2 mutational status predicts poor survival in myelofibrosis

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Primary myelofibrosis (PMF) is a serious myeloid neoplasm.
• Genetic mutations play a crucial role in PMF pathogenesis and prognosis.
• EZH2 mutations have been observed in various hematologic malignancies.

Purpose of the Study:

• To investigate the frequency and clinical significance of EZH2 mutations in PMF and post-myelofibrosis patients.
• To correlate EZH2 mutational status with clinical parameters and patient outcomes.

Main Methods:

• Genotyping of 370 PMF and 148 post-polycythemia vera/post-essential thrombocythemia (PPV/PET) MF patients for EZH2 mutations.
• Correlation analysis of mutational status with hematologic parameters, clinical features, and survival data.
• Multivariate analysis to identify independent predictors of survival.

Main Results:

• EZH2 mutations were detected in 5.9% of PMF, 1.2% of PPV-MF, and 9.4% of PET-MF patients.
• EZH2-mutated PMF patients presented with higher leukocyte and blast counts, larger spleens, and were more frequently high-risk (IPSS).
• EZH2 mutations were independently associated with reduced leukemia-free survival (LFS) and overall survival (OS) in PMF patients.

Conclusions:

• EZH2 mutations are an independent adverse prognostic factor in PMF.
• The presence of EZH2 mutations predicts shorter survival in PMF patients.
• Further research may explore therapeutic strategies targeting EZH2 in PMF.